Skip to main content

Table 2 Subject characteristics by chemotherapy categories (ITT population)

From: Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

  Fosaprepitant regimen Control regimen
n (%) GI or colorectal cancers (n = 135) Lung cancer (n = 129) Breast cancer (n = 110) Gynecologic cancer (n = 81) GI or colorectal cancers (n = 132) Lung cancer (n = 125) Breast cancer (n = 121) Gynecologic cancer (n = 71)
Single-day regimens
 Single MEC 4 (3.0) 12 (9.3) 10 (9.1) 9 (11.1) 4 (3.0) 21 (16.8) 3 (2.5) 7 (9.9)
 MEC + ≥1 LEC 24 (17.8) 96 (74.4) 90 (81.8) 72 (89) 16 (12.1) 88 (70.4) 106 (87.6) 61 (85.9)
 MEC + MEC 0 0 0 0 1 (0.8) 0 1 (0.8) 1 (1.4)
Multiple-day regimens
 MEC (day 1) + ≥1 LEC beyond day 1 100 (74.1) 18 (14.0) 0 0 94 (71.2) 14 (11.2) 0 2 (2.8)
 MEC (day 1) + ≥1 MEC + ≥1 LEC 5 (3.7) 0 0 0 15 (11.4) 0 0 0
Non-MEC regimens or no MEC on day 1
 LEC only 2 (1.5) 0 8 (7.3) 0 2 (1.5) 1 (0.8) 8 (6.6) 0
 Chemotherapy on day 2 onlya 0 0 0 0 0 0 0 0
 HEC regimens 0 3 (2.3) 2 (1.8) 0 0 1 (0.8) 3 (2.5) 0
 Cisplatin-based 3 (2.3) 1 (0.8)
 AC-based 2 (1.8) 3 (2.5)
  1. AC anthracycline + cyclophosphamide, HEC highly emetogenic chemotherapy, ITT intent to treat, LEC low emetogenic chemotherapy, MEC moderately emetogenic chemotherapy
  2. aSubject received MEC + LEC on day 2